KLRS — Kalaris Therapeutics Share News
0.000.00%
Last trade - 00:00Kalaris Therapeutics Q2 net loss narrows on lower administrative costs
Kalaris Therapeutics Inc expected to post a loss of 49 cents a share - Earnings Preview
Kalaris Therapeutics posts smaller-than-expected Q1 net loss
Brief: Kalaris Therapeutics Inc Q1 Operating Income USD -11.833 Million
Brief: Kalaris Therapeutics Reports Positive Initial Phase 1A Data For Th103
Brief: Kalaris Therapeutics Begins Phase 1B/2 Trial of TH103 for Neovascular Ascending Dose Study
Brief: Kalaris Begins Phase 1b/2 Study Of TH103 For Neovascular AMD With Multiple Ascending Dose Enrollment Underway
Brief: Kalaris Reports Second Quarter 2025 Financial Results And Provides Business Updates
Kalaris Therapeutics Inc expected to post a loss of 52 cents a share - Earnings Preview
Kalaris Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary
Kalaris Therapeutics Inc expected to post a loss of 77 cents a share - Earnings Preview
Brief: Kalaris Expands Board Of Directors Appointing Leone Patterson As Chair Of Audit Committee
Brief: Allovir's Reverse Stock Split Proposal Passes With 96.2 Mln Votes For
Brief: Allovir Inc - Diana Brainard Steps Down As CEO Of Allovir
Brief: Allovir And Kalaris Therapeutics Announce Merger To Form Company Focused On Retinal Diseases
Allovir Inc expected to post a loss of 9 cents a share - Earnings Preview
Brief: Octagon Capital Advisors Lp Reports 9.7% Passive Stake In Allovir Inc As Of Sept 30-SEC Filing
Allovir Inc reports results for the quarter ended in January - Earnings Summary
Allovir Inc expected to post a loss of 10 cents a share - Earnings Preview